

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): January 10, 2012

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-32085
(Commission
File Number)

36-4392754
(IRS Employer
Identification No.)

222 Merchandise Mart Plaza, Suite 2024, Chicago, Illinois 60654
(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: (312) 506-1200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Attached as Exhibit 99.1 hereto is an Investor Presentation dated January 10, 2012, which is incorporated herein by reference.

The information contained in or incorporated into this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.

Please refer to page 2 of Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.

Item 9.01 Financial Statements, Pro Forma Financial Information and Exhibits.**(d) Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Investor Presentation dated January 10, 2012

EXHIBIT INDEX

Exhibit No.

Description

99.1 Investor Presentation dated January 10, 2012

JANUARY 2012

Allscripts Investor Presentation

J.P. Morgan 30th Annual Healthcare Conference




Forward Looking Statement

This presentation contains forward-looking statements within the meaning of the federal securities laws. Statements regarding future events or developments, our future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on our results of operations or financial condition. Such risks, uncertainties and other factors include, among other things: the risk that we will not achieve the strategic benefits of the merger (the "Eclipsys Merger") with Eclipsys Corporation ("Eclipsys"); the possibility that the expected synergies and cost savings of the Eclipsys Merger will not be realized, or will not be realized within the expected time period; the risk that our business will not be integrated successfully with the business of Eclipsys; disruption from the Eclipsys Merger and related transactions making it more difficult to maintain business relationships with customers, partners and others; unexpected requirements to achieve interoperability certification pursuant to the Health Information Technology for Economic and Clinical Health Act, with resulting increases in development and other costs for us; the volume and timing of systems sales and installations, the length of sales cycles and the installation process and the possibility that our products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; errors or similar problems in our software products; the outcome of any legal proceeding that has been or may be instituted against us and others; compliance obligations under existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry, including possible regulation of our software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; the implementation and speed of acceptance of the electronic record provisions of the American Recovery and Reinvestment Act of 2009, as well as elements of the Patient Protection and Affordable Care Act (aka health reform) which pertains to health IT adoption; maintaining our intellectual property rights and litigation involving intellectual property rights; legislative, regulatory and economic developments; risks related to third-party suppliers and our ability to obtain, use or successfully integrate third-party licensed technology and breach of our security by third parties. See our Transition Report on Form 10-KT for the seven months ended December 31, 2010 and our subsequent filings with the SEC for a further discussion of these and other risks and uncertainties applicable to our business. The statements herein speak only as of their date and we undertake no duty to update any forward-looking statement whether as a result of new information, future events or changes in expectations.

OUR VISION

A Connected Community of Health™

Allscripts is the leading provider of Electronic Health Record (EHR), practice management and other clinical, revenue cycle, connectivity and information solutions for physicians, hospitals & post-acute organizations



Allscripts: Who We Are

OUR CLIENTS

- 180,000 Physicians
- 50,000 Physician Practices
- 1,500 Hospitals
- 10,000 Post-acute Facilities
- 27,000 Clinicians In Patients Homes Every Day

OUR COMPANY

- ~\$1.3BB 2010 Non-GAAP Revenue
- 6,000 Employees
- \$160MM in R&D & Growing
- Leader in Innovation
- ~\$3.5BB Market Capitalization
- 1 Complete Set of Solutions

Please see the Non-GAAP reconciliation and related footnotes in the appendix to this presentation.

Investment Highlights

MARKET LEADER • Diverse, industry leading client base

COMPLETE PRODUCT PORTFOLIO • Flexible, modern and complete solutions
• Maximizes opportunities to expand market and wallet share

DYNAMIC GROWTH MARKET • \$30BB Federal stimulus program drives healthcare IT adoption
• Low penetration of clinical solutions
• Shift to value-based care drives strong long-term secular demand trends

SIGNIFICANT OPERATING LEVERAGE • Proven and scalable platform for sales growth
• Legacy of product innovation
• Industry-leading brand awareness

HIGH QUALITY FINANCIAL MODEL • Exceptional visibility with \$2.7BB revenue backlog
• ~66% recurring revenue
• Strong free cash flow

Agenda



shift to value →

MARKET

Strong position

DIFFERENTIATION

GROWTH



Market: The Time is NOW

A National Problem

- Quality Issues
- Medical Errors / Safety Concerns
- Rising Cost
- Significant Waste



A Market that is Ready

- \$43BB¹ Opportunity
- \$30BB in Stimulus Funding
- ~35% Penetration in Physician Practices
- Rise in Employed Physicians
- Hospitals Driving Adoption



A Significant Opportunity

- We are at the *beginning* of what we expect will be the single fastest transformation of any industry in US history

1. McKinsey & Company

Market: Unsustainable Trend Requiring Change

VOLUME

- Fragmented providers and payments
- No uniform quality
- Fees for volume
- Demand increasing

VALUE

- Collaboration, connectivity
- Clinical, financial data, analysis
- Optimize outcomes
- Accountable care

Source: HFMA "Value in Healthcare: Current State & Future Directions June 2011"

Market: MDRX Addresses the Entire Market Opportunity

Acute/Ambulatory EHR Opportunity 2010-2014 = ~\$43BB



Source: McKinsey & Company

Market: Significant Ambulatory Potential

PRACTICE SIZE	TOTAL # OF PRACTICES	EHR PENETRATION (July '11)
1-3 Physicians	~186,000	~30%
4-9 Physicians	~28,000	~50%
10-25 Physicians	~6,900	~70%
26+ Physicians	~1,750	~85%
Total	226,650	~35%

Source: SK&A Information Services

Market: Acute Care Growth Drivers

HOSPITALS/HEALTH SYSTEMS

LEGACY REPLACEMENT CYCLE

- Obsolete mainframe systems
- Integrate acute/ambulatory systems
- Care Coordination

UNDER- UTILIZATION

- Only ~20%* of Hospitals at HIMSS Stage 4 adoption or higher
- Only 1%* at HIMSS Stage 7

Source: HIMSS Analytics EMR Adoption Model, July 2011




Differentiation: Leading Footprint Across the Market




Source: Allscripts Form 10Q Quarterly Report for period ended 9/30/11. GAAP revenue percentage based on 9 month period.



Differentiation: Open and Connected Portfolio



Differentiation: The Challenge to Deliver Meaningful Care




Differentiation: The New Architecture of Healthcare



Differentiation: Allscripts Approach

- Key stakeholders across the community (Allscripts Referral Network, Allscripts Community)
- All points of care and all applications within their organization



Differentiation: Clinical Outcomes Experience and Focus

THE ADVISORY BOARD COMPANY (APRIL 2011, "A PERSPECTIVE ON THE COMPANY")

“Clinical outcomes is the name of the game in ACOs. This is an area where we believe Allscripts holds a market lead, and needs to continue to focus on delivering more integrated outcomes modules for its client base.”

Differentiation: i20-Insights to Outcomes

Market values information, delivered to physicians leading to Better Results . . .
Better Outcomes . . . Insights to Outcomes

ALLSCRIPTS OPTIMALLY POSITIONED

- Largest client footprint
- Technology to connect
- The analytics to deliver information at the point of care

THIS SHOWS IN ALLSCRIPTS CLIENT RESULTS . . .

- Most utilization
- Most innovation
- Best outcomes

Differentiation: Deliver Solutions in a Value-Based Care Environment




Differentiation: Innovative Solutions

Mobile Platforms Accelerate Adoption







Growth: Long-Term Focus




Growth: Historical Performance



- **Non-GAAP Revenue**
CY 2009:
\$1,188MM



- **Non-GAAP Revenue**
CY 2010:
\$1,300MM



Note: Please see the Non-GAAP reconciliation and related footnotes in the appendix to this presentation.

Growth: Distribution Outpaces the Competition



Growth: Significant Cost Synergies


Key Cost Synergy Drivers

- Duplicative management structure
- Duplicative public company costs
- Duplicative back-end office and system integration
- Marketing

Projected Cost Synergies Over Three Years



Growth: Significant Client Sales Opportunity



Growth: Utilizing Strong Cash Flow to Enhance Value

CAPITALIZATION	ACTUAL 9/30/2011
Cash and Marketable Securities	\$87
Revolver (\$250mm)	0
Term Loan	377
Total Debt	\$377
Equity	1,439
Total Capitalization	\$1,816
Credit Statistics	
LTM EBITDA ⁽¹⁾	\$328
Total Debt / LTM EBITDA ⁽¹⁾	1.1x
Debt / Capitalization	20.8%

- Reduced debt by \$193MM since merger closed (8/10); \$45.5MM in Q3 2011
- Minimum required principal payments over next 12 months totals \$40MM
- Current borrowing cost <3%
- \$200MM, 3-year share repurchase program instituted in the second quarter of 2011
- Repurchased \$50MM of shares to date

¹ EBITDA is calculated as net income plus income tax expense, interest expense, stock-based compensation expense, depreciation & amortization, deferred revenue adjustments, certain one-time and transaction-related expenses, and non-recurring losses on the sale of investments minus non-recurring gains on the sale of assets, consistent with the calculation as defined in the Company's Senior Credit Facilities agreement.

Note: Please see the Non-GAAP reconciliation and related footnotes in the appendix to this presentation.

Growth: Non-GAAP Financial Outlook

(\$ in millions; except per share amounts)

	CY 2010 ACTUAL	CY 2011	2010 TO 2011 CHANGE
NON-GAAP REVENUE	\$1,300	\$1,455 - \$1,460	12%
NON-GAAP OPERATING MARGIN	19%	21%	+200 BPS
NON-GAAP NET INCOME	\$148	\$174 - \$179	17 – 21%
NON-GAAP DILUTED EPS	\$0.76	\$0.91 - \$0.93	20 – 22%

Note: Guidance provided by the company in a press release on November 3, 2011. This presentation does not subsequently update or reaffirm Allscripts financial guidance. Please see the Non-GAAP reconciliation and related footnotes in the appendix to this presentation.

In Summary....



JANUARY 2012

Allscripts Investor Presentation

J.P. Morgan 30th Annual Healthcare Conference



Appendix: Non-GAAP Reconciliations

Slide and Financial Measure	GAAP-Non-GAAP Reconciliation
Slide 4: 2010 Non-GAAP Revenue, Net Income	Slide 34
Slide 25: 2009 & 2010 Non-GAAP Revenue	Slide 34, 35
Slide 25: 2009 & 2010 Non-GAAP Operating Income	Slide 36, 37
Slide 25: Nine Months 2010 & 2011 Non-GAAP Operating Income	Slide 38
Slide 29: Trailing Twelve Months EBITDA	Slide 39

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP revenue and net income reconciliation for the twelve months ended December 31, 2010.

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information - 2010 Financial Information
(In millions, except per-share amounts)
(unaudited)

	Three Months Ended 3/31/10			Three Months Ended 6/30/10			Three Months Ended 9/30/2010			Three Months Ended 12/31/2010	Twelve Months Ended 12/31/2010	
	Allscripts	Eclipsys	Q1 2010	Allscripts	Eclipsys	Q2 2010	Allscripts	Eclipsys	Additional Int Exp(a)	Q3 2010	Q4 2010	CY 2010
Total revenue, as reported	\$184.4	\$128.4	\$312.8	\$191.4	\$134.4	\$325.8	\$191.2	\$51.2	\$0.0	\$242.4	\$316.2	\$1,197.2
Deferred revenue adjustment	0.5	0.0	0.5	0.6	0.0	0.6	0.5	6.7	0.0	7.2	20.9	29.2
Eclipsys results pre-merger period (7/1/10-8/23/10)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	79.5	0.0	79.5	0.0	79.5
Total non-GAAP revenue	\$184.9	\$128.4	\$313.3	\$192.0	\$134.4	\$326.4	\$191.7	\$137.4	\$0.0	\$329.1	\$337.1	\$1,305.9
Net income, as reported	\$18.6	\$5.4	\$24.0	\$13.1	\$1.6	\$14.7	\$5.4	(\$4.0)	\$0.0	\$1.4	(\$6.2)	\$33.9
Deferred revenue adjustment	0.3	0.0	0.3	0.3	0.0	0.3	0.3	4.0	0.0	4.3	12.7	17.6
Acquisition-related amortization	3.4	1.9	5.3	3.5	1.8	5.3	3.4	3.0	0.0	6.4	10.6	27.6
Stock-based compensation expense	2.4	3.4	5.8	1.8	2.9	4.7	4.0	0.0	0.0	4.0	2.3	16.8
Transaction-related expense	0.1	0.0	0.1	7.7	2.0	9.7	16.0	5.5	(1.9)	19.6	10.9	40.3
ARS Sales	0.0	0.0	0.0	0.0	0.9	0.9	0.0	0.0	0.0	0.0	0.0	0.9
Tax rate alignment	0.7	0.0	0.7	(0.2)	0.0	(0.2)	(1.6)	(0.2)	0.0	(1.8)	8.4	7.1
Eclipsys results pre-merger period (7/1/10-8/23/10)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	2.9	0.0	2.9
Non-GAAP net income	\$25.5	\$10.7	\$36.2	\$26.2	\$9.2	\$35.4	\$27.5	\$11.2	(\$1.9)	\$36.8	\$38.7	\$147.1

(a) Transaction-related expenses are fees and expenses, including legal, investment banking and accounting fees and other integration-related expenses, incurred in connection with announced transactions.

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP revenue reconciliation for the twelve months ended November 30, 2009 (Allscripts) and twelve months ended December 31, 2009 (Eclipsys).

Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per-share amounts)
(Unaudited)

	<u>Twelve Months Ended</u>		
	<u>Allscripts</u> <u>(11/30/2009)</u>	<u>Eclipsys</u> <u>(12/31/2009)</u>	<u>Non-GAAP</u>
Total revenue, as reported	\$661.1	\$519.1	\$1,180.2
Deferred revenue adjustment	9.7	8.0	\$17.7
Elimination of prepackaged medications	(9.7)	0.0	(\$9.7)
Total non-GAAP revenue	<u>\$661.1</u>	<u>\$527.1</u>	<u>\$1,188.2</u>

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP operating income reconciliation by quarter and twelve months ended December 31, 2009 (Eclipsys) and November 30, 2009 (Allscripts).

Allscripts Healthcare Solutions, Inc.
2009 Non-GAAP Financial Information
(In millions, except per-share amounts)
(Unaudited)

	Three Months Ended			Three Months Ended			Three Months Ended			Three Months Ended			Twelve Months Ended		
	2/21/09	3/31/09	Q1 2009	5/31/09	6/30/09	Q2 2009	8/31/09	9/30/09	Q3 2009	11/30/09	12/31/09	Q4 2009	11/30/09	12/31/09	CY 2009
	Allscripts	Eclipsys	Non-GAAP	Allscripts	Eclipsys	Non-GAAP	Allscripts	Eclipsys	Non-GAAP	Allscripts	Eclipsys	Non-GAAP	Allscripts	Eclipsys	Non-GAAP
Operating income, as reported	\$22.8	(\$0.1)	\$22.7	\$23.6	(\$2.2)	\$21.4	\$21.6	\$4.5	\$26.1	\$26.7	\$7.2	\$33.9	\$94.7	\$9.4	\$104.1
Deferred revenue adjustment	3.1	1.5	4.6	2.6	3.1	5.7	2.6	0.5	3.1	1.4	1.8	3.2	9.7	6.9	16.6
Acquisition-related amortization	6.1	3.1	9.2	5.7	3.1	8.8	5.7	3.1	8.8	5.7	3.1	8.8	33.2	12.4	35.6
Stock-based compensation expense	2.1	4.4	6.5	2.6	6.8	9.4	3.3	3.6	6.9	4.4	3.4	7.8	12.4	18.2	30.6
Transaction-related expense (a)	3.5	0.0	3.5	7.2	0.0	7.2	3.9	0.0	3.9	1.2	0.0	1.3	15.9	0.0	15.9
Restructuring	0.0	5.4	5.4	0.0	3.2	3.2	0.0	1.1	1.1	0.0	0.0	0.0	0.0	9.7	9.7
Elimination of prepackaged medications	(1.0)	0.0	(1.0)	(0.1)	0.0	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	(1.1)	0.0	(1.1)
Total non-GAAP operating income	\$36.6	\$14.3	\$50.9	\$41.6	\$14.0	\$55.6	\$37.1	\$12.8	\$49.9	\$39.5	\$15.5	\$55.0	\$134.8	\$56.6	\$211.5

(a) Transaction-related expenses are fees and expenses, including legal, investment banking and accounting fees and other integration-related expenses, incurred in connection with announced transactions.

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP operating income reconciliation by quarter and twelve months ended December 31, 2010.

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information - 2010 Financial Information
(In millions, except per-share amounts)
(unaudited)

	Three Months Ended			Three Months Ended			Three Months Ended			Three Months Ended	Twelve Months Ended	
	3/31/10			6/30/10			9/30/2010			12/31/2010	12/31/2010	
	Allscripts	Eclipsys	Q1 2010	Allscripts	Eclipsys	Q2 2010	Allscripts	Eclipsys	Additional Int Exp(a)	Q3 2010	Q4 2010	CY 2010
Operating income, as reported	\$32.0	\$10.7	\$42.7	\$20.5	\$5.4	\$25.9	\$6.0	(\$7.2)	\$0.0	(\$1.2)	\$9.5	\$76.9
Deferred revenue adjustment	0.5	0.0	0.5	0.6	0.0	0.6	0.5	6.7	0.0	7.2	20.9	29.2
Acquisition-related amortization	5.6	3.1	8.7	5.6	3.1	8.7	5.6	4.9	0.0	10.5	17.4	45.3
Stock-based compensation expense	3.9	3.7	7.6	2.9	3.7	6.6	6.6	0.0	0.0	6.6	3.7	24.5
Transaction-related expense (a)	0.2	0.0	0.2	12.5	3.5	16.0	26.1	9.1	0.0	35.2	17.8	69.2
Eclipsys results pre-merger period (7/1/10-8/23/10)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	4.7	0.0	4.7
Total non-GAAP operating income	\$42.2	\$17.5	\$59.7	\$42.1	\$15.7	\$57.8	\$44.8	\$18.2	\$0.0	\$63.0	\$69.3	\$249.8

(a) Transaction-related expenses are fees and expenses, including legal, investment banking and accounting fees and other integration-related expenses, incurred in connection with announced transactions.

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP operating income and margin reconciliation for the three and nine months ended September 30, 2011 and 2010.

Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(Unaudited)

	Three Months Ended	Three Months Ended	Nine Months Ended	Nine Months Ended
	9/30/11	9/30/10	9/30/11	9/30/10
Total revenue, as reported	\$368.8	\$242.4	\$1,060.9	\$618.2
Deferred revenue adjustment	2.6	7.2	20.1	8.3
Eclipsys results pre-merger period	0.0	79.5	0.0	342.3
Total non-GAAP revenue	\$371.4	\$329.1	\$1,081.0	\$968.8
Operating income (loss), as reported	\$37.4	(\$1.2)	\$94.0	51.4
Deferred revenue adjustment	2.6	7.2	20.1	8.3
Acquisition-related amortization	16.6	10.5	49.9	27.9
Stock-based compensation expense	9.9	6.6	25.8	20.8
Transaction-related expense (a)	8.8	35.2	32.1	51.4
Eclipsys results pre-merger period	0.0	4.7	0.0	20.7
Total non-GAAP operating income	\$75.3	\$63.0	\$221.9	\$180.5
Total non-GAAP operating income as a percentage of non-GAAP revenue	20.3%	19.1%	20.5%	18.6%

(a) Transaction-related expenses are fees and expenses, including legal, investment banking and accounting fees and other integration-related expenses, incurred in connection with announced transactions.

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP EBITDA reconciliation for the 12 months ended September 30, 2011

Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per-share amounts)
(Unaudited)

EBITDA Calculation (\$ in thousands)	Combined Results for Allscripts and Eclipsys for the 12 months ended 9/30/11
Net income, as reported	\$43.3
Taxes	38.8
Stock-based compensation expense	37.3
Depreciation and Amortization	121.0
Interest expense	23.3
Transaction-related expenses	23.3
Deferred revenue adjustment	41.0
Gain on Sale of Assets	(0.3)
Earnings before interest, taxes, depreciation and amortization	\$327.5

Footnotes Regarding Financial Guidance

Financial guidance was last provided by the company in a press release on November 3, 2011. This presentation does not subsequently update or reaffirm Allscripts financial guidance.

Allscripts non-GAAP guidance for calendar 2011 assumes the following adjustments: approximately \$1,458.0 million in GAAP revenue; approximately \$21.0 million, pre-tax for an acquisition-related deferred revenue adjustment. Non-GAAP guidance for calendar 2011 assumes the following adjustments to GAAP operating and net income: approximately \$66.5 million of acquisition-related amortization; approximately \$36.0 million in stock-based compensation expense; and approximately \$21.0 million in deferred revenue, all on a pre-tax basis. Allscripts 2011 non-GAAP net income and diluted earnings per share guidance assumes a 37.5-38.0 percent tax rate.

Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with generally accepted accounting principles, or GAAP. To supplement this information, Allscripts presents in this press release total non-GAAP revenue, gross profit, operating income and net income, including non-GAAP net income on a per share basis, which are non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. Total non-GAAP revenue consists of GAAP revenue as reported and Eclipsys revenue for periods prior to the August 24, 2010 consummation of the 2010 merger with Eclipsys (2010 Merger) and adds back the acquisition-related deferred revenue adjustment booked for GAAP purposes. Total non-GAAP gross profit consists of GAAP gross profit as reported and Eclipsys gross profit for periods prior to the consummation of the 2010 Merger and adds back the acquisition-related deferred revenue adjustment booked for GAAP purposes. Total non-GAAP operating income consists of GAAP operating income as reported and Eclipsys operating income for periods prior to the consummation of the 2010 Merger and adds back the acquisition-related deferred revenue adjustment booked for GAAP purposes and excludes acquisition-related amortization, stock-based compensation expense and transaction-related expenses. Non-GAAP net income consists of GAAP net income as reported and includes Eclipsys net income for periods prior to the consummation of the 2010 Merger, excludes acquisition-related amortization, stock-based compensation expense and transaction-related expenses, adds back the acquisition-related deferred revenue, in each case net of any related tax effects. Non-GAAP net income also includes a tax rate alignment adjustment.

Management also believes that non-GAAP revenue, gross profit, operating income and net income and non-GAAP net income on a per share basis provide useful supplemental information to management and investors regarding the underlying performance of the Company's business operations and facilitates comparisons of the separate 2010 pre-merger results of legacy Allscripts and legacy Eclipsys to that of the Company's 2010 post-merger results. Acquisition accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments that we have provided and discussed herein. Management also uses this information internally for forecasting and budgeting as it believes that the measure is indicative of the Company's core operating results. In addition, the Company uses non-GAAP revenue, operating income and/or net income to measure achievement under the Company's stock and cash incentive compensation plans. Note, however, that non-GAAP revenue, gross profit, operating income and net income and non-GAAP net income on a per share basis are performance measures only, and they do not provide any measure of the Company's cash flow or liquidity. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the reconciliation of non-GAAP financial measures with GAAP financial measures contained within the attached condensed consolidated financial statements.